Clinical trials: NSCLC, Stage IIIA
Non-Small Cell Lung Cancer
A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)
This study was designed to evaluate the safety and efficacy of neoadjuvant and adjuvant atezolizumab in participants with resectable Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT02927301
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
- Where
- 19 sites in United States
- Volunteers
- 181 people
- Sponsor
- Genentech, Inc.
Lung Neoplasms
Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC)
Primary Objective: To evaluate the toxicity/safety profile of docetaxel/cisplatin induction therapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by consolidation docetaxel/cisplatin in…
- Trial name
- NCT00174772
- Testing
- docetaxel and cisplatin followed by concurrent chemoradiotherapy with docetaxel and cisplatin + radiotherapy, docetaxel and cisplatin + radiotherapy followed by docetaxel and cisplatin
- Where
- 8 sites in Belgium, Finland and 6 more
- Volunteers
- 72 people
- Sponsor
- Sanofi
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer
Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer
This phase I/II trial is studying the side effects and best dose of azacitidine when given together with entinostat and to see how well they work in treating patients with recurrent advanced non-small cell lung cancer.
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
- Trial name
- NCT00387465
- Testing
- Azacitidine 30mg/m2, Entinostat, Azacitidine 40mg/m2
- Where
- 5 sites in United States
- Volunteers
- 94 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Breast Cancer
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer
- Trial name
- NCT00004065
- Testing
- tanespimycin
- Where
- 2 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery
This randomized phase III trial studies chemotherapy and bevacizumab to see how well they work compared to chemotherapy alone in treating patients with stage IB, stage II, or stage IIIA non-small cell lung cancer that was removed…
- Conditions
- Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT00324805
- Testing
- Bevacizumab, Cisplatin, Docetaxel
- Where
- 1,169 sites in United States, Canada and 3 more
- Volunteers
- 1,501 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer
Nimotuzumab in Combination With Radiochemotherapy for Patients With Stage IIIA/IIIB Non-small Cell Lung Cancer
Nimotuzumab (hR3) is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR).
- Trial name
- NCT02549261
- Testing
- nimotuzumab, Cisplatin, Etoposide
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
This phase I trial studies the side effects and best dose of genetically modified T-cell therapy in treating patients with receptor tyrosine kinase-like orphan receptor 1 positive (ROR1+) chronic lymphocytic leukemia (CLL)…
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Triple-Negative Breast Carcinoma
- Trial name
- NCT02706392
- Testing
- Laboratory Biomarker Analysis, ROR1 CAR-specific Autologous T-Lymphocytes
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Fred Hutchinson Cancer Center
Stage I Colon Cancer, Stage I Rectal Cancer
Survivorship Care Planning in Patients With Colorectal or Non-Small Cell Lung Cancer
Survivorship Care Planning may improve overall well-being and quality of life of colorectal and lung cancer survivors
- Conditions
- Stage I Colon Cancer, Stage I Rectal Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer
- Trial name
- NCT01741636
- Testing
- educational intervention, questionnaire administration, quality-of-life assessment
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- City of Hope Medical Center
Non Small Cell Lung Cancer
Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer
The purpose of the study is to investigate if treatment with zalutumumab in combination with chemotherapy and radiotherapy (chemo-radiation) will lead to a prolonged life in patients with lung cancer compared to patients treated…
- Trial name
- NCT00460551
- Testing
- Zalutumumab, Induction chemotherapy, Radiotherapy
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 13 people
- Sponsor
- Genmab
Depression, Lung Cancer
Depression Screening in Patients With Lung Cancer
RATIONALE: Screening tests may help doctors find depression in patients with lung cancer, allow doctors to recommend treatment for depression, and improve the patient's quality of life.
- Trial name
- NCT00404365
- Testing
- counseling intervention, screening questionnaire administration, study of socioeconomic and demographic variables
- Where
- 2 sites in United States
- Volunteers
- 241 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Cancer, Nonsmall Cell, Lung Cancer Stage III
Induction Chemo-Nivo in Unresectable Stage III NSCLC
The purpose of this study is to determine the response rate, safety, and effectiveness of a combination therapy in patients with lung cancer.
- Trial name
- NCT06003075
- Testing
- Nivolumab and Chemotherapy, Nivolumab, Post Induction Surgery
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Ralph G Zinner
Non-small Cell Lung Cancer
Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer
This is a prospective, multi-center, single-arm, phase 2 study aiming to assess the efficacy and safety of adjuvant use of Ensartinib in stage IB-IIIA non-small cell lung cancer (NSCLC) with positive ALK-fusion.
- Trial name
- NCT05241028
- Testing
- Ensartinib
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Hebei Medical University Fourth Hospital
Lung Cancer
Photodynamic Therapy Using HPPH in Treating Patients With Advanced Non-Small Cell Lung Cancer That Blocks the Air Passages
RATIONALE: Photodynamic therapy uses a drug, such as HPPH, that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed.
- Trial name
- NCT00528775
- Testing
- HPPH, endoscopic procedure
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Roswell Park Cancer Institute
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer
This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.
- Conditions
- Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
- Trial name
- NCT06732401
- Testing
- Biospecimen Collection, Ceralasertib, Computed Tomography
- Where
- 192 sites in United States
- Volunteers
- 630 people
- Sponsor
- National Cancer Institute (NCI)
NSCLC Stage IIIA/B, NSCLC Stage II
Construction of a Prognostic and Prediction Model for Perioperative Immunotherapy in NSCLC: A Multi - Omics Perspective
This research focuses on exploring biomarkers for the application of PD - 1/PD - L1 immune checkpoint inhibitors in the perioperative immunotherapy of lung cancer.
- Trial name
- NCT06856798
- Volunteers
- 120 people
- Sponsor
- Ziming Li
Lung Cancer
Paclitaxel and Carboplatin Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer That Cannot Be Removed During Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether paclitaxel and carboplatin is more effective than standard chemotherapy for…
- Trial name
- NCT00004887
- Testing
- carboplatin, cisplatin, ifosfamide
- Where
- United Kingdom
- Sponsor
- The Christie NHS Foundation Trust
Lung Cancer
Cisplatin, Pemetrexed Disodium, and Radiation Therapy Followed by Docetaxel in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin, pemetrexed disodium, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00301808
- Testing
- Cisplatin, Docetaxel, Pemetrexed disodium
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Non-small Cell Lung Cancer
Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
This study is an open label, multicenter, randomized phase II trial of consolidation immunotherapy with either nivolumab alone or the combination of nivolumab and ipilimumab following concurrent chemoradiation in patients with…
- Trial name
- NCT03285321
- Testing
- Nivolumab, Ipilimumab
- Where
- 12 sites in United States
- Volunteers
- 105 people
- Sponsor
- Greg Durm, MD
Lung Cancer
Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Specialized radiation therapy delivers a high dose of radiation directly to the tumor which may kill more…
- Trial name
- NCT00004253
- Testing
- carboplatin, paclitaxel, radiation therapy
- Where
- 2 sites in United States
- Sponsor
- Baptist Health South Florida
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
This randomized phase III trial studies pemetrexed disodium to see how well it works compared with erlotinib hydrochloride as second-line therapy in treating patients with non-small cell lung cancer that has spread to other…
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
- Trial name
- MARVEL (NCT00738881)
- Testing
- Erlotinib Hydrochloride, Pemetrexed Disodium
- Where
- 269 sites in United States, Canada
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)